Thymulin
Facteur Thymique Serique (FTS), Serum Thymic Factor, Zinc-Thymulin
The Ground Truth Score
four plain questions, never one numberA real thymic hormone with interesting biology and almost no controlled human trials behind it.
Bottom line
Thymulin is a zinc-dependent nonapeptide produced naturally by the thymus that plays a genuine role in T-cell maturation and immune regulation, but nearly all of the promising data (anti-inflammatory, analgesic, hair follicle) comes from rodent models, with only one small uncontrolled human topical study and no placebo-controlled trials for systemic use.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓2 mg SubQ once daily for 20 consecutive days, cycled 2-3x per year. No established human therapeutic protocol.
Reported, not prescribed. Verify your vial and your math.
The gist
- Used for immune support, hair loss, and anti-aging, with real animal data on T-cell maturation and anti-inflammatory pain relief via p38 MAPK.
- The only published human data is a single unblinded, 18-person topical hair study in a journal flagged as a potential predatory publisher. No placebo-controlled trial exists for systemic use.
- The catch: zinc alone probably accounts for a meaningful chunk of reported immune benefits, and nobody has run the trials needed to separate thymulin from the correction of ordinary zinc deficiency.
First documented human use
No controlled human trial has been completed.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Restores age-related thymic function and T-cell counts
- Reduces chronic inflammation and inflammatory pain
- Stimulates hair follicle growth in androgenetic alopecia
- Bridges the thymus-neuroendocrine axis for systemic rejuvenation
- Reverses zinc-deficiency immune decline in older adults
The data behind each bullet
What actually backs it
Thymulin reduces inflammatory cytokines and attenuates inflammatory pain
Multiple rat and mouse studies show thymulin reduces hyperalgesia and pro-inflammatory cytokines (TNF-a, IL-1b, IL-6) via p38 MAPK inhibition and spinal microglia suppression. No human pain trials.
PubMed: Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways (PMID 30851702) ↗Topical zinc-thymulin promotes hair growth in androgenetic alopecia
One open-label uncontrolled study (n=18, 17 male, 1 female, ages 35-90) found significant hair assessment improvement after 6+ months of topical spray. No placebo arm, no blinding. Published in Hair Therapy and Transplantation 2017. NOTE: This is the only published human data on thymulin as an active compound. The journal is published by Longdom Publishing SL, a subsidiary of OMICS Group. OMICS is listed on Beall's list of potential predatory publishers and was subject to a US$50 million FTC ruling in 2018 for deceptive practices including publication with little or no peer review. The Vickers study should be read with this context in mind and not treated as equivalent to peer review in a reputable journal.
Longdom/Hair Therapy (Beall's-listed publisher): Vickers et al. 2017 - Zinc-Thymulin Alopecia. Publisher credibility concerns noted above. ↗Thymulin activity declines with aging and can be partially restored by zinc supplementation
Well-characterized in both human serum studies and animal models. Circulating thymulin drops measurably with age; zinc repletion restores activity in vitro. Multiple independent labs have confirmed this mechanism. This is the most solid piece of thymulin biology.
PubMed: Age-related thymus involution; zinc reverses thymulin secretion defect (PMID 8582786) ↗Thymulin supports T-cell differentiation and immune reconstitution
Strong mechanistic and animal data. Thymulin drives thymocyte maturation and T-cell subset function. Observational correlations exist in immunodeficient humans. No RCT of thymulin administration improving human T-cell outcomes.
PMC: Thymus-Neuroendocrine Axis review (PMC2688715) ↗A synthetic thymulin-related analogue peptide (PAT) has analgesic potency comparable to NSAIDs in animal pain models
Rat studies with PAT, a synthetic analogue of thymulin (not native thymulin itself), show dose-dependent reduction of mechanical and thermal hyperalgesia comparable to steroidal and non-steroidal drugs. This evidence is for an analogue compound, not for native thymulin directly. Species translation to humans is completely untested for either compound.
PubMed: Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide (PAT, a synthetic analogue, not native thymulin) in rats (PMID 12110619) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
ASSUMED (established in animals, not confirmed in humans): Thymulin binds specific receptors on immature thymocytes and peripheral T-cells, driving differentiation of T-cell subsets and enhancing NK cell activity. Zinc is required for correct receptor-binding conformation. In the CNS, thymulin appears to modulate microglial activation and suppress pro-inflammatory cytokine production via p38 MAPK pathway inhibition. In hair follicles, thymulin is hypothesized to prolong the anagen (growth) phase by acting on follicular immune privilege. The zinc-thymulin complex declines with age as the thymus involutes, which may contribute to immune senescence.
Dosing & handling
What users and clinicians report
2 mg subcutaneous injection daily for 20 days, cycled 2-3 times per year. Topical zinc-thymulin sprays used in the alopecia study at unspecified concentrations. Some protocols co-administer 15-25 mg elemental zinc daily.
Reported dose is not prescribed and comes from community protocols with no pharmacokinetic basis in humans. The biggest dosing risk is zinc toxicity from aggressive co-dosing (copper depletion at chronic >40 mg/day). Reconstitution stability of lyophilized thymulin is unknown.
Timing & food
No human data to guide timing. Subcutaneous protocols are typically morning administration. Topical alopecia use was applied to scalp daily with no time-of-day specification in the Vickers study.
Half-life
Not established in humans. Peptide is a 9-amino acid nonapeptide likely subject to rapid enzymatic degradation in serum. Animal models suggest lymphoid tissue targeting within 90 minutes of subcutaneous injection but half-life numbers are not published for human pharmacokinetics.
Reconstitution sensitivity
Unknown. Lyophilized thymulin is assumed to require refrigeration and bacteriostatic water reconstitution consistent with other research peptides, but stability data specific to thymulin is not published. Zinc-complexed form may have different stability than the free peptide.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low. Thymulin appears in peptide forums and clinic blogs but generates far less community discussion than BPC-157, TB-500, or Thymosin alpha-1. Confounded heavily with Thymalin (a different crude thymic extract product widely used in Russian longevity protocols).
Consistency
Inconsistent. Immune and energy reports mixed. Hair users report slow partial improvement. Many who report benefits are stacking with zinc correction, minoxidil, or TRT making isolation impossible.
Source credibility
Low. Community reports are overwhelmingly anecdotal with no separation from confounders. Clinic testimonials are not independent evidence.
- Anecdote: Some users on injectable thymulin 20-day protocols report reduced frequency of minor illness over the following months, though baseline health, zinc status, and concurrent stack make attribution speculative.
- Anecdote: Topical zinc-thymulin users targeting hair loss report very slow partial improvement (5-6 months before visible change), with high dropout before the 6-month threshold where the Vickers study showed effects.
- Anecdote: A subset of longevity-protocol users pair thymulin with Thymosin alpha-1 and report synergistic immune improvement. No separation of effects is possible.
- Anecdote: Energy and mood uplift reported by some users is almost certainly confounded by zinc repletion (a common deficiency) rather than thymulin-specific activity.
Placebo risk, High
Primary marketed outcomes (immune resilience, energy, hair thickness) are subjective or slow-moving. No objective biomarker shifts attributable to thymulin alone have been demonstrated in human subjects. Zinc correction effect alone is plausible for many reported benefits.
Risk panel
What could go wrong
Adverse events
No serious adverse events reported in any human or animal study. The one human topical study (n=18) reported zero adverse systemic effects or local irritation over 4-10 months. That study was published in a journal from a publisher (Longdom/OMICS) on Beall's list of potential predatory publishers, which limits confidence in the peer review quality of this safety finding. Systemic injectable use in humans has no published controlled safety data.
Theoretical concerns
Immune modulation carries theoretical risk of tipping autoimmune balance in susceptible individuals. Zinc co-dosing at high levels (above 40 mg/day chronically) risks copper depletion independently of thymulin.
Contraindications
No established contraindications. Theoretical caution in active autoimmune disease, organ transplant recipients on immunosuppression, or active malignancy given T-cell stimulatory activity.
Honest unknowns
Long-term effects of exogenous thymulin in adults with a functional (non-involuted) thymus are completely unknown. No pharmacokinetic data for subcutaneous dosing in humans. No data on interaction with TRT, GLP-1 agonists, or other peptide protocols.
Confound watch
Users who report immune improvements are often simultaneously correcting zinc deficiency (which alone improves thymulin activity), running peptide stacks (BPC-157, TB-500, Thymosin alpha-1), or on TRT (which has independent immune-modulatory effects). Hair growth users frequently combine with minoxidil or finasteride. Attribution is nearly impossible.
History
Discovery → first use → status
- 1977Bach and Dardenne at Institut Necker (Paris) isolate and sequence Facteur Thymique Serique (FTS) from porcine and human serum. Amino acid sequence confirmed as a 9-residue peptide requiring equimolar zinc for biological activity.
- 1980sSurge of interest in thymulin and other thymic peptides for autoimmune disease, cancer, and immunodeficiency. Most clinical work used crude thymic extracts (Thymalin) rather than pure thymulin. Interest waned as results were inconsistent.
- 2000s-2010sRenewed animal research establishes thymulin as a neuroendocrine mediator with analgesic and anti-inflammatory properties beyond immune function. Thymulin-related synthetic analogues explored as pain targets (USPTO patent 7309690).
- 2017Vickers et al. publish the only human clinical data on thymulin as an active compound: a small open-label topical study in 18 alopecia patients showing hair density improvements with no adverse events. Published in a Longdom/OMICS journal (see claim note on publisher credibility).
Verification
The COA standard, applied
Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citations corrected 2026-06-22: (1) PMID 12110619 analgesic claim relabeled to make explicit this is a thymulin analogue (PAT), not native thymulin; (2) Vickers 2017 Longdom citation flagged with Beall's-list predatory publisher disclosure (Longdom is a Longdom/OMICS subsidiary, subject to US$50M FTC ruling 2018); these disclosures added to claim text, verification sources, and risk section.
The full verification standard →Sources
Where this comes from
- PMC: The Thymus-Neuroendocrine Axis (PMC2688715) - Comprehensive review of thymulin biology ↗· Best single academic source. Covers mechanism, neuroendocrine interactions, and therapeutic potential. Published Annals of the New York Academy of Sciences 2009.
- PubMed: Thymulin prevents pro-inflammatory cytokines in mice (PMID 18991101) ↗· Animal anti-inflammatory data. Representative of the rodent evidence base that most marketed claims rest on.
- Longdom Open Access (Beall's-listed publisher): Vickers et al. Zinc-Thymulin androgenetic alopecia 2017 ↗· The only published human data using thymulin as the active compound. Small, unblinded, no placebo arm. Published in a journal by Longdom/OMICS, a publisher on Beall's list of potential predatory publishers (subject to a US$50M FTC deceptive-practices ruling in 2018). Do not overweight. Do not treat as equivalent to peer review in a reputable journal.
- PubMed: Age-related thymic involution and zinc-thymulin (PMID 8582786) ↗· Solid mechanistic basis for why zinc repletion improves thymulin activity in aging. Does not validate exogenous thymulin injection.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.